Spinal muscular atrophy is a fatal congenital neuromuscular disease caused by SMN1 gene mutation. Effective treatment has not established yet. As a strategy of the treatment, modification for SMN2 splicing is thought to be a promising approach. We previously discovered compound A is effective to modify the SMN2 splicing using mini gene system. Subsequently, we tried to search for similar compound that would modify the SMN2 splicing safely. However, we didn't find the effective compounds for SMN2 splicing correction during the study period.